CF PHARMTECH (02652) announced that its H shares have been officially included in the list of eligible securities under both the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect, effective March 9, 2026. According to the announcement, qualifying mainland Chinese investors will be able to trade the company’s H shares through these channels once the inclusion takes effect.

The announcement highlights expectations that this development may help increase the company’s shareholder base and boost trading liquidity of its H shares. CF PHARMTECH, Inc. is primarily engaged in inhalation drug delivery technology, focusing on complex inhalation formulations and integrated capabilities in device engineering, precision drug delivery, and global regulatory filing.

The company stated that it is advancing its innovative pipeline in China, the United States, and Europe, emphasizing efforts in respiratory and nasal disease treatments, as well as strategic expansion into pulmonary fibrosis, pulmonary arterial hypertension, rare pulmonary infections, and potential nose-to-brain delivery for central nervous system disorders. It also noted a developing commercialization network in China, along with globally compliant manufacturing systems, to support its long-term goal of becoming an international pharmaceutical enterprise.